Case Study Originally Published on Tempus.com
Bristol Myers Squibb is advancing its efforts to improve equitable access to high‑quality cancer care by applying real‑world insight to where care delivery often breaks down. In a recent case study focused on advanced non‑small cell lung cancer (aNSCLC), BMS worked in collaboration with Tempus to deploy the Tempus Next Pathways program across 13 community‑based health systems. The initiative provided a unified, longitudinal view of the patient journey using de‑identified, near real‑time clinical intelligence, helping to surface where and why patients may fall off guideline‑directed pathways, particularly around biomarker testing.
By illuminating practical barriers to care delivery and variation across settings, including geography and community context, the work supports measurable progress in closing testing gaps and informs BMS’ broader approach to health equity. These insights reinforce BMS’ focus on pairing innovation with accountability, using data to better understand real‑world care and help ensure that advances in oncology reach more patients, including those in historically medically underserved communities.
Read the Case Study here: Tempus Next Pathways unlocked critical insights into the aNSCLC patient journey with Bristol Myers Squibb (BMS) – Tempus
